MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock,...
$2,897,611
Net cash provided by
financing activities
$2,897,611
Net increase
(decrease) in cash and cash...
-$89,646,698
Canceled cashflow
$2,897,611
Maturities of investments -
marketable securities
$10,100,000
Stock-based compensation
expense
$5,559,766
Prepaid research and
development
-$487,083
Accounts payable
$429,251
Accrued expenses and
other current...
$43,372
Net cash provided by
(used in) investing...
-$80,484,587
Net cash used in
operating activities
-$12,059,722
Canceled cashflow
$10,100,000
Canceled cashflow
$6,519,472
Purchases of investments -
marketable securities
$90,584,587
Net loss
-$16,380,840
Prepaid expenses and
other current assets
$949,439
Non-cash accretion on
marketable securities
$814,923
Change in fair value
contingent consideration
$373,354
Other assets
$60,638
Back
Back
Cash Flow
source: myfinsight.com
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)